|
Synonyms: AMG-827 | AMG827 | Kyntheum® | Lumicef® | Siliq®
brodalumab is an approved drug (Japan (2016), FDA (2017), EMA (2017))
Compound class:
Antibody
Comment: Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It targets the interleukin 17 receptor A (IL17RA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Treatment with brodalumab carries the warning that the drug is associated with suicidal ideation and behaviour [5]. The mechanistic explanation for an increased suicide risk is unknown, and this risk factor has not been associated with other approved drugs that target the same pathway (e.g. secukinumab and ixekizumab which both target the IL-17 ligand rather than the IL-17 receptor). |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Psoriasis |
Disease Ontology:
DOID:8893 |
Approved therapeutic for plaque psoriasis. | |
| Asthma |
Disease Ontology:
DOID:2841 OMIM: 600807 |
Clinical candidate for asthma. | |
| Psoriatic arthritis |
Disease Ontology:
DOID:9008 |
Clinical candidate for PsA. | |
